Orbit Genomics, a pioneer in redefining precision medicine, today announced the appointment of Julie Silber to its Board of Directors. Silber brings over 25 years of experience in investor relations, capital markets, corporate strategy, and board advisory, with expertise in the diagnostics and life sciences sectors to support Orbit’s next phase of growth in precision health.
“Julie’s broad understanding of the diagnostics landscape, capital markets, and strategic communication makes her an ideal addition to our board,” said Dede Willis, CEO of Orbit Genomics. “Her ability to translate complex science into compelling narratives that resonate with investors and stakeholders will be instrumental as we scale our efforts to redefine preventive healthcare.”
Silber has spent the past 10 years advising diagnostics, genomics and life science companies through growth, transformation, and capital raises. She has served in leadership roles across North America and Europe, guiding public and private companies on investor strategy, corporate governance, and M&A communications. As a former Interim CFO and serial entrepreneur, she brings a rare blend of financial acumen, operational insight, and boardroom perspective.
Silber also holds a Certificate in Corporate Governance from the Wharton School at the University of Pennsylvania. She has also advised numerous boards on best practices in transparency, long-term value creation, and stakeholder communication.
“I’m honored to join the board of Orbit Genomics at such a pivotal time in its journey,” said Silber. “Orbit’s work in uncovering personal disease risk through advanced genomic technology is not only scientifically exciting, but also deeply meaningful. I look forward to contributing to the company’s vision of a healthier, more proactive future.”